Combining Human Organoids and Organ-on-a-Chip Technology to Model Intestinal Region-Specific Functionality
May 5th, 2022
26K views
Biopsy-derived intestinal organoids and organ-on-a-chips technologies are combined into a microphysiological platform to recapitulate region-specific intestinal functionality.
Overview
This protocol demonstrates the integration of biopsy-derived intestinal organoids with organ-on-a-chip technology to create a microphysiological platform that mimics the functionality of the human intestine. This innovative approach allows for the study of pharmacokinetics, drug-drug interactions, and intestinal barrier dysfunction.
Key Study Components
Area of Science
- Neuroscience
- Biology
- Pharmacology
Background
- Biopsy-derived intestinal organoids provide a model for studying intestinal physiology.
- Organ-on-a-chip technology enhances the experimental control of biological systems.
- This method allows for the reproduction of the complex intestinal epithelium.
- Understanding gut functions is crucial for drug development and disease prevention.
Purpose of Study
- To create a physiologically relevant intestine chip.
- To predict pharmacokinetics and drug interactions.
- To study intestinal epithelial barrier dysfunction.
Methods Used
- Integration of organoids with organ-on-a-chip technology.
- Control of mechanical cues and biochemical gradients.
- Seeding of organoids as a critical step in the protocol.
- Emulation of human intestinal physiology.
Main Results
- The platform successfully mimics the complexity of the human intestine.
- Enhanced understanding of cellular and molecular gut functions.
- Improved predictions of pharmacokinetics and pharmacodynamics.
- Potential to identify drug candidates that prevent inflammatory damage.
Conclusions
- The microphysiological platform is a valuable tool for intestinal research.
- It provides insights into normal and pathological gut functions.
- This approach can aid in the development of new therapeutic strategies.
Frequently Asked Questions
What are intestinal organoids?
Intestinal organoids are 3D structures derived from intestinal stem cells that mimic the architecture and function of the intestine.
How does organ-on-a-chip technology work?
Organ-on-a-chip technology involves creating microfluidic devices that simulate the physiological conditions of human organs.
What is the significance of studying intestinal barrier dysfunction?
Studying intestinal barrier dysfunction is crucial for understanding various gastrointestinal diseases and developing effective treatments.
How can this platform predict drug interactions?
The platform allows researchers to observe how drugs interact with intestinal cells in a controlled environment, providing insights into their pharmacokinetics.
What are the potential applications of this research?
This research can be applied in drug development, disease modeling, and understanding gut-related disorders.
Executive Industry Relevance
Combining human organoids with organ-on-a-chip technology enables physiologically relevant modeling of region-specific intestinal function, supporting predictive pharmacokinetics and mechanistic de-risking in early drug discovery. This platform addresses the challenge of recapitulating complex epithelial-endothelial interactions and barrier dynamics, providing actionable insights for target validation and compound triage. Its ability to model drug metabolism, transport, and inflammatory barrier disruption enhances translational continuity and portfolio decision-making.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses in human-relevant intestinal microenvironments.
- Supports mechanistic de-risking by modeling epithelial barrier integrity and region-specific responses.
- Facilitates functional target validation through quantitative assessment of drug metabolism and cytokine signaling.
- Improves predictive confidence for advancing candidates targeting intestinal pathways.
Screening & Assay Development
- Provides validated, reproducible biological systems for compound screening and absorption studies.
- Standardizes quantitative readouts for permeability, transport, and metabolic activity.
- Enables scalable, reusable assay platforms for evaluating drug-drug interactions and barrier function.
- Supports robust evaluation of compound effects on epithelial and endothelial compartments.
Translational & Preclinical Research
- Aligns in vitro findings with disease-relevant mechanisms such as leaky gut and inflammatory signaling.
- Enables modeling of patient-specific disease mechanisms and therapeutic responses.
- Supports risk-adjusted advancement by providing human-relevant data on drug safety and efficacy.
- Facilitates biomarker discovery through transcriptomic and cytokine profiling under controlled conditions.
Pipeline & Workflow Integration
This intestine chip platform bridges early discovery, lead identification, and preclinical validation by providing a modular, human-relevant system for hypothesis testing and compound evaluation.
- Discovery Biology: Supports hypothesis-driven studies of intestinal transport, metabolism, and barrier function.
- Screening: Delivers reproducible, quantitative outputs for permeability and metabolic assays.
- Analytics: Enables measurement of CYP3A4 induction, cytokine secretion, and transcriptomic changes.
- Translational Research: Models disease-relevant barrier disruption and inflammatory responses for preclinical alignment.
- Enterprise Reuse: Offers a standardized, scalable platform adaptable to multiple intestinal regions and disease contexts.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in intestinal drug discovery.
- Operational Value: Enhances standardization, reproducibility, and scalability of complex in vitro models.
- Strategic Value: Improves go/no-go decisions and capital efficiency by providing actionable human-relevant data.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of intestinally targeted assets.
Implementation Considerations
- Requires expertise in organoid culture, microfluidics, and quantitative assay development.
- Demands access to specialized instrumentation for chip culture and analytical readouts.
- Necessitates cross-team standardization of seeding density, flow conditions, and assay protocols.
- Adaptable to different intestinal regions and disease models with protocol optimization.
- Dependent on quality of biopsy-derived organoids and endothelial cell sources for reproducibility.
Biopharma FAQs
Why does null hypothesis testing matter for CYP3A4 induction assays?
Null hypothesis testing in CYP3A4 induction assays ensures that observed increases in enzyme activity or gene expression are statistically significant, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation improve IFNγ barrier disruption studies?
Isolating IFNγ as the independent variable allows precise attribution of barrier disruption effects, enabling mechanistic de-risking and clearer interpretation of inflammatory pathway involvement in intestinal models.
What do quantitative permeability measurements enable in colon chip assays?
Quantitative permeability measurements provide actionable data on barrier integrity, supporting cross-condition comparisons and informing compound selection for further development.
Why are replication requirements critical for cytokine secretion profiling?
Replication ensures that cytokine secretion profiles are reproducible and reliable, facilitating cross-functional collaboration and confidence in translational biomarker discovery.
What statistical analysis is required before implementing transcriptomic profiling?
Statistical analysis of transcriptomic data is essential to identify significant gene expression changes, validate biological relevance, and support data-driven advancement decisions in the discovery pipeline.
Chapters in this video
0:05
Introduction
1:24
Seeding of Organoid Fragments
3:14
Dynamic Culture of Intestine Chip
4:19
CYP450 Induction in the Intestine Chip
5:49
Sample Preparation for LC-MS Analysis
7:15
Stimulation with IFNγ
8:24
Results: CYP3A4 Induction and IFNγ Stimulation in the Intestine Chip
10:12
Conclusion
